OLUMIANT(R) Significantly Improved Hair Regrowth to At Least 80% Scalp Coverage as Early as 24 Weeks Across First Completed Phase 3 Studies for Alopecia Areata

INDIANAPOLIS, Sept. 30, 2021 -- (Healthcare Sales & Marketing Network) -- Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ: INCY) announced today detailed results from two pivotal Phase 3 trials (BRAVE-AA1 and BRAVE-AA2), which found once-daily OLUMIA... Biopharmaceuticals Eli Lilly, OLUMIANT, baricitinib, alopecia areata
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news